Literature DB >> 31725893

Larotrectinib in TRK fusion-positive pediatric B-cell acute lymphoblastic leukemia.

Denis M Schewe1, Lennart Lenk1, Fotini Vogiatzi1, Dorothee Winterberg1, Annika V Rademacher1, Swantje Buchmann1, Dahlia Henry2, Anke K Bergmann3, Gunnar Cario1, Michael C Cox2.   

Abstract

Entities:  

Year:  2019        PMID: 31725893      PMCID: PMC6880891          DOI: 10.1182/bloodadvances.2019000700

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


× No keyword cloud information.
  8 in total

1.  Genomic precision medicine: on the TRK.

Authors:  Sarah Elitzur; Shai Izraeli
Journal:  Blood       Date:  2018-08-23       Impact factor: 22.113

2.  Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial.

Authors:  Christina Peters; Martin Schrappe; Arend von Stackelberg; André Schrauder; Peter Bader; Wolfram Ebell; Peter Lang; Karl-Walter Sykora; Johanna Schrum; Bernhard Kremens; Karoline Ehlert; Michael H Albert; Roland Meisel; Susanne Matthes-Martin; Tayfun Gungor; Wolfgang Holter; Brigitte Strahm; Bernd Gruhn; Ansgar Schulz; Wilhelm Woessmann; Ulrike Poetschger; Martin Zimmermann; Thomas Klingebiel
Journal:  J Clin Oncol       Date:  2015-03-09       Impact factor: 44.544

3.  Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.

Authors:  H Glucksberg; R Storb; A Fefer; C D Buckner; P E Neiman; R A Clift; K G Lerner; E D Thomas
Journal:  Transplantation       Date:  1974-10       Impact factor: 4.939

4.  Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Authors:  Alexander Drilon; Theodore W Laetsch; Shivaani Kummar; Steven G DuBois; Ulrik N Lassen; George D Demetri; Michael Nathenson; Robert C Doebele; Anna F Farago; Alberto S Pappo; Brian Turpin; Afshin Dowlati; Marcia S Brose; Leo Mascarenhas; Noah Federman; Jordan Berlin; Wafik S El-Deiry; Christina Baik; John Deeken; Valentina Boni; Ramamoorthy Nagasubramanian; Matthew Taylor; Erin R Rudzinski; Funda Meric-Bernstam; Davendra P S Sohal; Patrick C Ma; Luis E Raez; Jaclyn F Hechtman; Ryma Benayed; Marc Ladanyi; Brian B Tuch; Kevin Ebata; Scott Cruickshank; Nora C Ku; Michael C Cox; Douglas S Hawkins; David S Hong; David M Hyman
Journal:  N Engl J Med       Date:  2018-02-22       Impact factor: 91.245

Review 5.  TRKing down an old oncogene in a new era of targeted therapy.

Authors:  Aria Vaishnavi; Anh T Le; Robert C Doebele
Journal:  Cancer Discov       Date:  2014-12-19       Impact factor: 39.397

6.  Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.

Authors:  Theodore W Laetsch; Steven G DuBois; Leo Mascarenhas; Brian Turpin; Noah Federman; Catherine M Albert; Ramamoorthy Nagasubramanian; Jessica L Davis; Erin Rudzinski; Angela M Feraco; Brian B Tuch; Kevin T Ebata; Mark Reynolds; Steven Smith; Scott Cruickshank; Michael C Cox; Alberto S Pappo; Douglas S Hawkins
Journal:  Lancet Oncol       Date:  2018-03-29       Impact factor: 41.316

7.  Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

Authors:  Kathryn G Roberts; Yongjin Li; Debbie Payne-Turner; Richard C Harvey; Yung-Li Yang; Deqing Pei; Kelly McCastlain; Li Ding; Charles Lu; Guangchun Song; Jing Ma; Jared Becksfort; Michael Rusch; Shann-Ching Chen; John Easton; Jinjun Cheng; Kristy Boggs; Natalia Santiago-Morales; Ilaria Iacobucci; Robert S Fulton; Ji Wen; Marcus Valentine; Cheng Cheng; Steven W Paugh; Meenakshi Devidas; I-Ming Chen; Shalini Reshmi; Amy Smith; Erin Hedlund; Pankaj Gupta; Panduka Nagahawatte; Gang Wu; Xiang Chen; Donald Yergeau; Bhavin Vadodaria; Heather Mulder; Naomi J Winick; Eric C Larsen; William L Carroll; Nyla A Heerema; Andrew J Carroll; Guy Grayson; Sarah K Tasian; Andrew S Moore; Frank Keller; Melissa Frei-Jones; James A Whitlock; Elizabeth A Raetz; Deborah L White; Timothy P Hughes; Jaime M Guidry Auvil; Malcolm A Smith; Guido Marcucci; Clara D Bloomfield; Krzysztof Mrózek; Jessica Kohlschmidt; Wendy Stock; Steven M Kornblau; Marina Konopleva; Elisabeth Paietta; Ching-Hon Pui; Sima Jeha; Mary V Relling; William E Evans; Daniela S Gerhard; Julie M Gastier-Foster; Elaine Mardis; Richard K Wilson; Mignon L Loh; James R Downing; Stephen P Hunger; Cheryl L Willman; Jinghui Zhang; Charles G Mullighan
Journal:  N Engl J Med       Date:  2014-09-11       Impact factor: 91.245

8.  ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition.

Authors:  Kathryn G Roberts; Laura J Janke; Yaqi Zhao; Aman Seth; Jing Ma; David Finkelstein; Steve Smith; Kevin Ebata; Brian B Tuch; Stephen P Hunger; Charles G Mullighan
Journal:  Blood       Date:  2018-06-07       Impact factor: 25.476

  8 in total
  2 in total

Review 1.  Molecular markers in ALL: Clinical implications.

Authors:  Shunsuke Kimura; Charles G Mullighan
Journal:  Best Pract Res Clin Haematol       Date:  2020-06-07       Impact factor: 3.020

Review 2.  Has Ph-like ALL Superseded Ph+ ALL as the Least Favorable Subtype?

Authors:  Thai Hoa Tran; Sarah K Tasian
Journal:  Best Pract Res Clin Haematol       Date:  2021-10-23       Impact factor: 3.020

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.